China National Medicines Corporation Ltd.
600511
Category
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 10.61 | -17.79% |
| 2024 | 12.91 | 26.69% |
| 2023 | 10.19 | -4.93% |
| 2022 | 10.72 | -20.97% |
| 2021 | 13.56 | -49.60% |
| 2020 | 26.91 | 107.55% |
| 2019 | 12.96 | 6.47% |
| 2018 | 12.18 | -32.89% |
| 2017 | 18.14 | -52.39% |
| 2016 | 38.11 | 7.58% |
| 2015 | 35.42 | 15.14% |
| 2014 | 30.76 | 40.20% |
| 2013 | 21.94 | 5.56% |
| 2012 | 20.79 | -1.87% |
| 2011 | 21.18 | -44.69% |
| 2010 | 38.30 | -29.19% |
| 2009 | 54.09 | 53.22% |
| 2008 | 35.30 | -43.44% |
| 2007 | 62.42 | 127.88% |
| 2006 | 27.39 | 115.03% |
| 2005 | 12.74 | -30.45% |
| 2004 | 18.32 | -28.44% |
| 2003 | 25.59 | -40.19% |
| 2002 | 42.79 | -28.15% |
| 2001 | 59.56 | -29.55% |
| 2000 | 84.55 | 0.00% |
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 26.02 | 145.17% |
US
|
|
| - | - |
US
|
|
| 34.08 | 221.08% |
US
|
|
| - | - |
US
|
|
| 45.62 | 329.81% |
AU
|
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.